Introduction {#Sec1}
============

Prognostic information about the novel coronavirus disease (COVID-19) pandemic is important for patient care. While China reported prediction models on length of stay and mortality^[@CR1]^ and US data is emerging, predictors for hospitalization have not been well defined yet.^[@CR2],\ [@CR3]^ Our study aims to identify correlates for hospitalization in a large cohort of COVID-19 patients in Michigan.

Methods {#Sec2}
=======

We performed a retrospective review of patients diagnosed with SARS-CoV2 infection by a positive RT-PCR on nasopharyngeal swab from the largest healthcare system in Southeast Michigan (8 hospitals), through April 1, 2020. We abstracted demographics, comorbidities, medications, and calculated disease burden with the Charlson Comorbidity Index (CCI).^[@CR4]^ Logistic regression evaluated associations and multivariate analyses, including variables with *p* value \<0.20 on univariate analysis (SPSS).

Results {#Sec3}
=======

Of 2040 COVID-19 positive patients, 1305 (64.0%) were hospitalized and 735 (36.0%) were evaluated in the Emergency Department (ED), discharged home, and did not require reevaluation within 14 days.

Univariate correlates of hospitalization included:: Age \> 60 (OR:3.4, 95% CI: 2.8--4.1), male (OR:1.4, 95% CI: 1.2--1.7), Caucasian (OR:1.4, 95% CI: 1.0--2.0), obesity (OR:1.5, 95% CI: 1.2--1.9), CCI \> 2 (OR:5.2, 95% CI: 4.2--6.5), ACE-I/ARB use (OR:2.4, 95% CI: 2.0--2.9), tachycardia (heart rate \> 100 beats/min) (OR:1.6, 95% CI: 1.3--1.9), tachypnea (respiratory rate \> 20 breaths/min, OR:5.3, 95% CI: 4.0--7.1), and hypoxia (oxygen saturation \< 90%, OR:21.7, 95% CI: 8.0--59.1, Table [1](#Tab1){ref-type="table"}**)**.

Independent correlates of hospitalization included: Age \> 60 (aOR:2.1, 95% CI: 1.4--3.1), CCI \> 2 (aOR:3.2, 95% CI: 2.1--4.8), male (aOR:1.9, 95% CI: 1.5--2.5), obesity (aOR:1.8, 95% CI: 1.4--2.4), ACE-I/ARB use (aOR:1.5, 95% CI: 1.1--2.0), tachycardia (aOR:1.5, 95% CI: 1.1--2.0), tachypnea (aOR:2.9, 95% CI: 2.1--4.1), and hypoxia (aOR:15.0, 95% CI: 4.7--48.0, Table [1](#Tab1){ref-type="table"}).

Discussion {#Sec4}
==========

We found that older age (\>60 years), obesity, CCl \> 2, ACE-I/ARB use, and male sex as independent correlates for hospitalization in COVID-19 patients, after controlling for objective clinical findings of illness severity of tachycardia, tachypnea, and hypoxia. Older age and higher comorbidity burden have also been reported as risk factors for mortality in hospitalized COVID-19 patients.^[@CR2],\ [@CR5],\ [@CR6]^ This information can provide insight to help guide triage decisions of COVID-19 patients in the emergency center and help appropriate allocation of healthcare resources in the time of a pandemic. The main limitations of our study include its retrospective nature, limited follow-up time, and potential inaccuracies in the medical records. Additionally, the high admission rate in our cohort suggests high patient acuity hence limiting the utility of the identified correlates in other settings such as outpatient offices.

Conclusion {#Sec5}
==========

Older age, medical comorbidities, obesity, ACE-I/ARB use, and male sex are independent correlates of hospitalization in COVID-19 patients presenting to the emergency department.Table 1Univariate and multivariate analyses of demographic, comorbidity and clinical indices among hospitalized and outpatient cohorts**MortalityUnivariate AnalysisOR (95% CI)*P*valueDemographics**Age \> 60 years3.4 (2.8,4.1)\<0.0005Male1.4 (1.2,1.7)\<0.0005Caucasian Race compared to African-American1.4 (1.0,2.0)0.037Other Race compared to African-American0.87 (0.61,1.3)0.467Smoking history1.4 (0.83, 2.3)0.212BMI \> 301.5 (1.2,1.9)0.002**Medications**NSAID use1.0 (0.85,1.2)0.831ACE-I/ARB use2.4 (2.0,2.9)\<0.0005**Comorbidities**CCI \> 25.2 (4.2,6.5)\<0.0005HTN4.4 (3.6,5.4)\<0.0005DM3.9 (3.0,5.1)\<0.0005CKD8.0 (5.0,12.9)\<0.0005COPD2.5 (1.6,4.0)\<0.0005CAD/PAD4.2 (2.8, 6.1)\<0.0005Cancer2.4 (1.5,4.0)\<0.0005Heart Failure4.4 (2.3,8.6)\<0.0005OSA2.2 (1.5,3.3)\<0.0005Bronchial Asthma1.4 (1.0,2.0)0.053CVA or TIA14.3 (5.3, 39.2)\<0.0005VTE3.0 (1.7,5.5)\<0.0005Dementia2.5 (0.70,8.6)0.162Immunosuppression1.2 (0.46,3.2)0.685Peptic Ulcer Disease5.4 (1.3,23.3)0.023Connective Tissue Disease1.9 (0.95,4.00)0.068**Vitals Signs**Tachycardia (HR \> 100 beats/min)1.6 (1.3,1.9)\<0.0005Tachypnea (RR \> 20 breaths/min)5.3 (4.0,7.1)\<0.0005Hypoxia (SpO2 \< 90%)21.7 (8.0,59.1)\<0.0005**Multivariate AnalysisVariableaOR (95% CI)*P*value**Age \> 602.1 (1.4,3.1)0.015CCI \> 2^1^3.2 (2.1,4.8)\<0.0005Male1.9 (1.5,2.5)\<0.0005Caucasian Race compared to African-American1.4 (0.83,2.3)0.220ACE-I/ARB use1.5 (1.1,2.0)0.015Other race compared to African-American0.90 (0.53,1.6)0.709BMI \> 301.8 (1.4,2.4)\<0.0005Tachycardia (HR \> 100 bpm)1.5 (1.1,2.0)0.007Tachypnea (RR \> 20 breaths/min)2.9 (2.1,4.1)\<0.0005Hypoxia (SpO2 \< 90%)15.0 (4.7,48.0)\<0.0005Abbreviations: CKD, chronic kidney disease; COPD: chronic obstructive pulmonary disease; OSA: Obstructive Sleep Apnea; HTN, hypertension; VTE, venous thromboembolic disease; TIA, Transient Ischemic Attack; CVA, Cerebrovascular Accident; NSAIDs: Non-steroidal anti-inflammatory medication; ACE-I: angiotensin converting enzyme-inhibitor; ARB: angiotensin receptor blocker; OR: Odds ratio; aOR: adjusted odds ratio; CI, confidence interval; CAD, coronary artery disease; PAD, peripheral artery disease; CCI, Charlson Comorbidity Index; RR: respiratory rate; HR, heart rate; SpO2, oxygen saturation; BMI, body mass index; bpm, beats per minuteCCI utilized in multivariate analysis as surrogate for comorbidities
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